Home > Neurology > EAN 2022 > Migraine > Erenumab more than doubles plasma CGRP levels

Erenumab more than doubles plasma CGRP levels

Presented By
Dr Nina Vashchenko, Sechenov First Moscow State Medical University, Russia
Conference
EAN 2022
Doi
https://doi.org/10.55788/3739333d
The calcitonin gene-related peptide (CGRP) receptor blocker erenumab is associated with a significant increase in CGRP levels in peripheral blood after 6 months of therapy in a real-life population of migraine patients. The efficacy and safety of erenumab was comparable with that in clinical trials. Erenumab differs from the other available CGRP monoclonal antibodies by not blocking CGRP but its receptor. By doing this, one would expect the CGRP level to increase as a normal physiological reaction. Seemingly paradoxical, erenumab would in that case have a positive effect on migraine while causing CGRP levels to rise. Up until now, it was unknown what effect erenumab has on plasma CGRP levels, if any at all. Dr Nina Vashchenko (Sechenov First Moscow State Medical University, Russia) and her group set out to investigate this [1]. Included were 58 migraine patients who were treated with the CGRP monoclonal antibody erenumab. Of these, 50 were women and...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on